Sakamoto Shingo, Kusuhara Hiroyuki, Miyata Kenji, Shimaoka Hiroyuki, Kanazu Takushi, Matsuo Yumiko, Nomura Kohji, Okamura Noboru, Hara Seijiro, Horie Kazutoshi, Baba Takahiko, Sugiyama Yuichi
Developmental Research Laboratories, Shionogi & Co., Ltd., Osaka, Japan.
J Pharmacol Exp Ther. 2007 Aug;322(2):610-8. doi: 10.1124/jpet.106.116426. Epub 2007 Apr 30.
Methyl 1-(3,4-dimethoxyphenyl)-3-(3-ethylvaleryl)-4-hydroxy-6,7,8-trimethoxy-2-naphthoate (S-8921) is a novel inhibitor of the ileal apical sodium-dependent bile acid transporter (ASBT/SLC10A2) developed for the treatment of hypercholesterolemia. The present study investigated the hypocholesterolemic action of S-8921 glucuronide (S-8921G) in rats. The plasma concentration of S-8921G was higher than that of S-8921 after single oral administration of S-8921 in normal rats, and S-8921G was excreted into the bile (13% dose). Oral administration of either S-8921 or S-8921G reduced the serum total cholesterol, particularly nonhigh-density lipoprotein cholesterol, in hypercholesterolemic normal rats. In Gunn rats devoid of UDP glucuronosyltransferase-1A activity, S-8921G was undetectable both in the plasma and bile specimens, and only S-8921G administration significantly reduced the serum nonhigh-density lipoprotein cholesterol. An in vitro inhibition study showed that glucuronidation converts S-8921 to a 6000-fold more potent inhibitor of human ASBT (K(i) = 18 nM versus 109 microM). S-8921G was detected both in the portal plasma and loop when S-8921 was administered into the loop of the rat jejunum, although the cumulative amount of S-8921G recovered in the bile was 5-fold greater than that in the loop. The uptake of S-8921G by freshly prepared rat hepatocytes was saturable, and sodium-dependent and -independent systems were involved. Organic anions, such as bromosulfophthalein, estrone 3-sulfate, and taurocholic acid, inhibited the uptake. These results suggest that UDP glucuronosyltransferase-1 isoforms play a critical role in the hypocholesterolemic action of S-8921 by converting S-8921 to a more potent ASBT inhibitor, and organic anion transporter(s) are also involved in its pharmacological action through the biliary excretion of S-8921G.
1-(3,4-二甲氧基苯基)-3-(3-乙基戊酰基)-4-羟基-6,7,8-三甲氧基-2-萘甲酸甲酯(S-8921)是一种新型的回肠顶端钠依赖性胆汁酸转运体(ASBT/SLC10A2)抑制剂,用于治疗高胆固醇血症。本研究调查了S-8921葡萄糖醛酸苷(S-8921G)在大鼠体内的降胆固醇作用。在正常大鼠单次口服S-8921后,S-8921G的血浆浓度高于S-8921,且S-8921G经胆汁排泄(剂量的13%)。口服S-8921或S-8921G均可降低高胆固醇血症正常大鼠的血清总胆固醇,尤其是非高密度脂蛋白胆固醇。在缺乏UDP葡萄糖醛酸基转移酶-1A活性的Gunn大鼠中,血浆和胆汁标本中均未检测到S-8921G,只有给予S-8921G能显著降低血清非高密度脂蛋白胆固醇。一项体外抑制研究表明,葡萄糖醛酸化使S-8921转化为对人ASBT抑制作用强6000倍的抑制剂(Ki = 18 nM对109 μM)。当将S-8921注入大鼠空肠肠袢时,在门静脉血浆和肠袢中均检测到S-8921G,尽管胆汁中回收的S-8921G累积量比肠袢中的大5倍。新鲜制备的大鼠肝细胞对S-8921G的摄取具有饱和性,涉及钠依赖性和非依赖性系统。有机阴离子,如溴磺酞、雌酮3-硫酸盐和牛磺胆酸,可抑制摄取。这些结果表明,UDP葡萄糖醛酸基转移酶-1同工型通过将S-8921转化为更强效的ASBT抑制剂,在S-8921的降胆固醇作用中起关键作用,有机阴离子转运体也通过S-8921G的胆汁排泄参与其药理作用。